Results 101 to 110 of about 11,886 (196)

Adjustment of Eculizumab Dosage Pattern in Patients with Atypical Hemolytic Uremic Syndrome with Suboptimal Response to Standard Treatment Pattern

Case Reports in Nephrology, 2016
In patients with atypical hemolytic uremic syndrome (aHUS), complement blocking by eculizumab rapidly halts the process of thrombotic microangiopathy and it is associated with clear long-term hematologic and renal improvements.
Camino García Monteavaro, Carmen Peralta Roselló, Borja Quiroga, José María Baltar Martín, Lorena Castillo Eraso, Fernando de Álvaro Moreno, Alberto Martínez Vea, María Teresa Visus-Fernández de Manzanos   +7 more
doaj   +1 more source

Eculizumab in secondary atypical haemolytic uraemic syndrome [PDF]

, 2017
Background. Complement dysregulation occurs in thrombotic microangiopathies (TMAs) other than primary atypical haemolytic uraemic syndrome (aHUS). A few of these patients have been reported previously to be successfully treated with eculizumab.
Jarque, Ana, Portoles, Jose, Gonzalez-Parra, Emilio, Portolés Pérez, José María, Ávila, Ana, Sevillano, Ángel, Romera, Ana María, Borrego, Josefa, Quintana, Luis F, María Romera, Ana, Mendizabal, Santiago, Aljama, Pedro, Gavela, Eva, Macía, Manuel, Quintana, Luis F., Morales, Enrique, Gracia-Iguacel, Carolina, Rojas-Rivera, Jorge, Rodriguez-de-Cordoba, Santiago, Rodríguez de Córdoba, Santiago, Espinosa, Mario, Huerta, Ana, González Parra, Emilio José, Román, Elena, Arjona, Emi, Rabasco, Cristina, López, Antía, Blasco, Miquel, Cavero, Teresa, Fuentes, Carolina, Praga, Manuel, Cao, Mercedes, Praga Terente, Manuel, Gracia Iguacel, Carolina Marta, García, Alba   +34 more
core   +1 more source

Anti-complement Treatment for Paroxysmal Nocturnal Hemoglobinuria: Time for Proximal Complement Inhibition? A Position Paper From the SAAWP of the EBMT

Frontiers in Immunology, 2019
The treatment of paroxysmal nocturnal hemoglobinuria has been revolutionized by the introduction of the anti-C5 agent eculizumab; however, eculizumab is not the cure for Paroxysmal nocturnal hemoglobinuria (PNH), and room for improvement remains. Indeed,
Antonio M. Risitano, Antonio M. Risitano, Serena Marotta, Serena Marotta, Patrizia Ricci, Luana Marano, Camilla Frieri, Fabiana Cacace, Michela Sica, Austin Kulasekararaj, Austin Kulasekararaj, Rodrigo T. Calado, Phillip Scheinberg, Rosario Notaro, Regis Peffault de Latour, Regis Peffault de Latour   +15 more
doaj   +1 more source

Eculizumab for Thrombotic Microangiopathy Associated with Antibody-Mediated Rejection after ABO-Incompatible Kidney Transplantation

Case Reports in Transplantation, 2017
Thrombotic microangiopathy is a form of antibody-mediated rejection (ABMR): it is the main complication of ABO-incompatible (ABOi) kidney transplantation (KT). Herein, we report on two cases of ABMR with biological and histological features of thrombotic
Luca Lanfranco, Melanie Joly, Arnaud Del Bello, Laure Esposito, Noelle Cognard, Peggy Perrin, Bruno Moulin, Nassim Kamar, Sophie Caillard   +8 more
doaj   +1 more source

Application of eculizumab, a terminal complement inhibitor, in the management of atypical hemolytic uremic syndrome in a 14-month-old Chinese pediatric patient: a case report

Frontiers in Pediatrics
Eculizumab, a recombined humanized monoclonal antibody which possesses high affinity for the complement protein C5, is a therapeutic agent utilized in the treatment of atypical hemolytic uremic syndrome (aHUS) by inhibiting the terminal complement ...
Xin Wei, Xinzhu Liu, Yingying Yu, Wei Xie, Wentao Luo, Ye Tu, Shuhong Bu, Guimei Guo   +7 more
doaj   +1 more source

Eculizumab Therapy Leads to Rapid Resolution of Thrombocytopenia in Atypical Hemolytic Uremic Syndrome

Advances in Hematology, 2014
Eculizumab is highly effective in controlling complement activation in patients with the atypical hemolytic uremic syndrome (aHUS). However, the course of responses to the treatment is not well understood. We reviewed the responses to eculizumab therapy
Han-Mou Tsai, Elizabeth Kuo
doaj   +1 more source

Ravulizumab: a novel C5 inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria

Therapeutic Advances in Hematology, 2019
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare stem cell disorder characterized by hemolytic anemia, bone marrow failure, and thrombosis. Until recently, the complement inhibitor, eculizumab, was the only United States Food and Drug Administration ...
Robert M. Stern, Nathan T. Connell
doaj   +1 more source

Complement inhibitor therapy in atypical hemolytic uremic syndrome (aHUS): evaluating the economic impact of introducing eculizumab biosimilars in Germany

BMC Nephrology
Background Eculizumab, a humanized monoclonal antibody, inhibits activation of complement component C5. For patients with atypical hemolytic uremic syndrome, the introduction of eculizumab has markedly improved survival, restoring life expectancy close ...
Isabell Kaufhold, Daniel Lewkowicz, Danila Seidel, Paul Thomas Brinkkoetter, Florian Kron   +4 more
doaj   +1 more source

Eculizumab Therapy [PDF]

Biology of Blood and Marrow Transplantation, 2014
openaire   +2 more sources

Eculizumab or ravulizumab treatment effect in people with neuromyelitis optica spectrum disorder: a plain language summary of three studies

Journal of Comparative Effectiveness Research
What is this summary about? Neuromyelitis optica spectrum disorder (NMOSD for short) is a rare autoimmune health condition, meaning that the body’s natural defense system (the immune system) attacks the body’s own tissues.
Alfredo Damasceno, Mariano Marrodan
doaj   +1 more source